Company

Syndax

Syndax Pharmaceuticals Inc

SNDX pharma USA

Quick answer

Syndax is a pharma company (SNDX) headquartered in NEW YORK, NY, USA with 24 tracked pipeline programs.

Pipeline (24)

Revumenib

Acute Myeloid Leukemias

Phase 3 · small_molecule · active

1 trials project

Atezolizumab

Metastatic Cancer

Phase 2 · small_molecule · terminated

1 trials project

Axatilimab

Idiopathic Pulmonary Fibrosis

Phase 2 · small_molecule · active

1 trials project

Azacitidine

Non-Small Cell Lung Cancer

Phase 2 · small_molecule · completed

1 trials project

Durvalumab

Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 · small_molecule · completed

1 trials project

Entinostat

Metastatic Cholangiocarcinoma

Phase 2 · small_molecule · completed

1 trials project

Entinostat

Melanoma

Phase 2 · small_molecule · completed

1 trials project

Entinostat

Renal Cell Carcinoma

Phase 2 · small_molecule · active

2 trials project

Entinostat

Non-Small-Cell Lung Carcinoma

Phase 2 · small_molecule · completed

1 trials project

Entinostat

Non Small Cell Lung Cancer

Phase 2 · small_molecule · terminated

2 trials project

Entinostat

ER+ Breast Cancer

Phase 2 · small_molecule · completed

1 trials project

Entinostat

Lymphoma

Phase 2 · small_molecule · active

1 trials project

Entinostat

Hodgkin's Lymphoma

Phase 2 · small_molecule · terminated

1 trials project

Fulvestrant

Breast Cancer

Phase 2 · small_molecule · terminated

1 trials project

Pembrolizumab

Metastatic Uveal Melanoma

Phase 2 · small_molecule · completed

1 trials project

Pembrolizumab

Bladder Cancer

Phase 2 · small_molecule · active

1 trials project

Revumenib

Colorectal Cancer

Phase 2 · small_molecule · completed

1 trials project

Revumenib

Acute Myeloid Leukemia

Phase 2 · small_molecule · active

2 trials project

Revumenib

Relapsed Adult AML

Phase 2 · small_molecule · active

1 trials project

Revumenib

Leukemia

Phase 2 · small_molecule · active

1 trials project

SNDX-5613

Acute Myeloid Leukemia

Phase 2 · small_molecule · active

1 trials project

SNDX-6352

Coronavirus

Phase 2 · small_molecule · terminated

1 trials project

Venetoclax

Acute Myeloid Leukemia

Phase 2 · small_molecule · active

1 trials project

axatilimab

Chronic Graft-versus-host-disease

Phase 2 · small_molecule · active

Drugs (1)

revumenib citrate

REVUFORJ

Patents (6)

US 12168054

Method of treating cancer using a combination of entinostat and an anti-CSF-1R a

Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12000829

Selection of patients for combination therapy

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11919901

Inhibitors of the menin-MLL interaction

Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11397184

Selection of patients for combination therapy

Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10226472

Methods for the treatment of breast cancer

Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026